Not Disclosed

Drug Name: Not Disclosed
Company: ProMIS Neurosciences
Location: Canada
Drug Type: Vaccine, Protein Biologic
Conditions: ALS, Alzheimer’s disease
Mechanism Type: Misfolded SOD1 Clearance
Mechanism: ProMIS is developing therapeutic approaches for immunization against disease-specific epitopes (DSE) of misfolded or aggregated mutant superoxide dismutase-1 (SOD-1). The company uses a dual approach of passive immunization with anti-SOD1 monoclonal antibodies, in combination with activate immunization with an anti-SOD1 vaccine to produce antibodies in the patient’s body. The vaccine is expected to eliminate the misfolded protein, while sparing wild-type SOD-1.
U.S. Status for ALS: Preclinical

[1] Promis Neurosciences. Promis Neurosciences, 2016. Accessed 9 Mar 2016.

Last updated March 9th, 2016

Share this: